Versus Systems Inc. (VS)
NASDAQ: VS · Real-Time Price · USD
1.070
+0.030 (2.88%)
Oct 8, 2026, 4:00 PM EDT - Market closed
Versus Systems Revenue
Versus Systems had revenue of $6.82K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $2.18M, up 7,931.28% year-over-year. In the year 2025, Versus Systems had annual revenue of $2.18M with 3,711.30% growth. That makes Versus Systems the 42,892nd largest company in the world by revenue and 5,906th in the United States.
Revenue (ttm)
$2.18M
Revenue Growth
+7,931.28%
P/S Ratio
4.39
Revenue / Employee
$302,638
Employees
5
Market Cap
6.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.18M | 2.13M | 3,711.30% |
| Dec 31, 2024 | 57.29K | -213.88K | -78.87% |
| Dec 31, 2023 | 271.17K | -837.67K | -75.54% |
| Dec 31, 2022 | 1.11M | 340.19K | 44.26% |
| Dec 31, 2021 | 768.65K | -621.37K | -44.70% |
| Dec 31, 2020 | 1.39M | 888.87K | 177.36% |
| Dec 31, 2019 | 501.15K | 499.96K | 41,872.53% |
| Dec 31, 2018 | 1.19K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Inuvo | 52.29M |
| Nvni Group | 37.83M |
| Next Technology Holding | 12.92M |
| Jet.AI | 10.48M |
| Infobird | 7.13M |
| Knorex | 6.04M |
| Orangekloud Technology | 4.42M |
| Cyngn | 387.13K |
VS News
- 20 hours ago - IBN Announces Latest Episode of The Stock2Me Podcast Featuring Versus Systems CEO Luis Goldner and Leadership Team - GlobeNewsWire
- 15 days ago - Versus Systems announces appointment of Goldenberg as CFO - TheFly
- 15 days ago - Versus Systems Appoints Brian Goldenberg as Chief Financial Officer - GlobeNewsWire
- 3 months ago - VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors - Business Wire
- 5 months ago - Prodigii Licenses VERSES® Technology - GlobeNewsWire
- 5 months ago - VERSES® Expands Commercial Relationship with Major Global Investment Firm - GlobeNewsWire
- 6 months ago - VERSES® Announces Closing of Second Tranche of Private Placement Offering of Units - GlobeNewsWire
- 6 months ago - VERSES® Announces Closing of Private Placement Offering of Units - GlobeNewsWire